Viking Therapeutics

Viking Therapeutics is the GLP-1 underdog that became the most volatile mid-cap biotech of 2024-2025. The stock went from USD 25 (early 2024) to USD 105 (February 2024 on Phase 2 VENTURE injectable data showing 13.1% placebo-adjusted weight loss at 13 weeks), back to USD 28 by Q1/2026 after Eli Lilly's orforglipron Phase 3 (May 2025) printed superior efficacy with pristine safety. The current USD 30.27 reflects a market that has fully discounted the once-celebrated VK2735 program — and that's where the asymmetric thesis sits.

The active program is VK2735 oral (Phase 2 VENTURE-Oral) — pivotal data expected H2/2026. The differentiator vs Lilly's orforglipron is mechanism: VK2735 is a dual GLP-1/GIP agonist (similar to Lilly's tirzepatide injectable), where orforglipron is GLP-1 monotherapy. Best-case scenario: VK2735 oral achieves 15-18% weight loss at 28 weeks (vs orforglipron 14.7%) with manageable GI tolerability. Worst case: tolerability profile makes VK2735 oral commercially uncompetitive against the soon-to-be-launched orforglipron (FDA late 2026).

Beyond obesity, Viking has VK2809 MASH (Phase 3 readout 2027) and VK0214 X-ALD (Phase 2 rare disease, orphan-grade). The MASH program competes against Madrigal's Rezdiffra (approved 2024) — VK2809 has potential best-in-class biopsy data but commercial positioning is now harder. Cash runway through Q4/2027 at current burn USD 95-110 M/quarter.

Smart-money positioning has been wildly volatile. RA Capital Management held 5.1% peak (early 2024), trimmed to 1.4% by Q1/2026 after the Lilly orforglipron readout. Baker Brothers Advisors entered Q3/2025 at USD 38-45 with 4.2% stake — biotech specialist conviction that the M&A optionality remains. Perceptive Advisors 3.6%. The notable Q1/2026 entry: Boxer Capital 2.8% at USD 28-34 — Boxer rarely buys post-disappointment without conviction the asset is M&A-attractive.

Insider activity has been muted. CEO Brian Lian (founder, ex-Amgen) sold USD 4.2 M in early 2024 at USD 85-105 (10b5-1 program, well-timed but planned), no insider buying since. CFO Greg Zante exercised 80 K options and held all shares Q1/2026 — small positive signal. The notable absence: no board-level open-market buying despite the 70% drawdown, which the bears use as evidence that insiders see the orforglipron risk as terminal.

Short interest is elevated at 18.7% of float — among highest in biotech mid-cap. The thesis-short argument is that orforglipron tolerability + 12-month earlier launch combined with Lilly's commercial muscle makes VK2735 oral DOA. The bull-short-squeeze setup is if VENTURE-Oral H2/2026 readout is positive.

Forward P/E -6.7x is meaningless — Viking will not be GAAP profitable for years. The relevant valuation lens is risk-adjusted NPV with binary scenarios. Bull case (VENTURE-Oral hits 15-18% weight loss + 20% discontinuation): risk-adjusted NPV USD 110-140/share. Bear case (failed readout): USD 12-18/share. Base case (mixed result, useful but not blockbuster): USD 35-50/share. Analyst mean target USD 92.33 (+205% upside) is bull-case weighted; Cantor USD 130 (Overweight), HC Wainwright USD 115 (Buy), JPM USD 78 (Overweight), Stifel USD 28 (Hold). The wide analyst spread USD 28-130 reflects pure binary uncertainty. Cash + non-obesity-NPV USD 22-40/share establishes the lower bound below which the stock should not trade absent further bad news.

1. Q2 2026 cash position + burn update: Sets the runway clock — below USD 700M cash exiting Q2/2026 increases probability of pre-readout capital raise
2. H2 2026 VENTURE-Oral Phase 2 28-week readout: THE event — positive readout creates 4-6x upside, negative creates 60% downside; this is the binary that determines next 3 years
3. H1 2027 potential M&A approach: Conditional on positive readout, strategic M&A approaches typically materialize within 6 months — takeout math USD 65-100/share if positive readout confirms dual-agonist oral commercial viability

Viking Therapeutics is the binary asymmetric biotech bet of 2026 — the one where the stock either goes 4-6x or down 60% based on a single Phase 2 readout. The Boxer Capital + Baker Brothers presence gives me modest confidence that the institutional community sees the M&A optionality as real even in the failed-readout scenario. I would size this 0.5-1% of equity with explicit understanding of binary outcome — never size larger than I can afford to lose entirely. Stop at USD 18 (below cash-floor + non-obesity-NPV), no add until VENTURE-Oral confirmation. The Lilly orforglipron is the dominant overhang — its 2027 launch will set commercial benchmarks Viking has to beat to justify the M&A premium. This is a thesis-bet on dual-mechanism oral being structurally superior to GLP-1 monotherapy oral, which is biologically plausible but unproven at the necessary tolerability level.